GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio
GSK will acquire Nuvalent for $10.6 billion in cash ($124 per share), gaining three NSCLC programs—zidesamtinib (ROS1) and neladalkib (ALK) as late-stage, potentially best-in-class therapies plus NVL-330 (HER2) and a preclinical portfolio—along with a platform for lung-cancer expansion. The deal, expected to close after regulatory approvals in 2026, is designed to be revenue- accretive from 2027 and-core EPS accretive by 2029 (including synergies and reprioritisation), financed largely by debt and cash with no expected rating impact and maintaining GSK’s dividend policy.